Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Mast Cells*/metabolism ; Airway Remodeling*/immunology ; Hypertension, Pulmonary*/immunology ; Hypertension, Pulmonary*/pathology ; Pulmonary Artery*/immunology ; Pulmonary Artery*/pathology ; Lysophospholipids*/biosynthesis ; Fatty Acids, Unsaturated*/biosynthesis; Humans ; Animals

Mast cells are responsible for IgE-dependent allergic responses, but they also produce various bioactive mediators and contribute to the pathogenesis of various cardiovascular diseases, including pulmonary hypertension (PH). The importance of lipid mediators in the pathogenesis of PH has become evident in recent years, as exemplified by prostaglandin I2, the most central therapeutic target in pulmonary arterial hypertension. New bioactive lipids other than eicosanoids have also been identified that are associated with the pathogenesis of PH. However, it remains largely unknown how mast cell-derived lipid mediators are involved in pulmonary vascular remodeling. Recently, it has been demonstrated that mast cells produce epoxidized n-3 fatty acid (n-3 epoxides) in a degranulation-independent manner, and that n-3 epoxides produced by mast cells regulate the abnormal activation of pulmonary fibroblasts and suppress the progression of pulmonary vascular remodeling. This review summarizes the role of mast cells and bioactive lipids in the pathogenesis of PH. In addition, we introduce the pathophysiological role and therapeutic potential of n-3 epoxides, a mast cell-derived novel lipid mediator, in the pulmonary vascular remodeling in PH. Further knowledge of mast cells and lipid mediators is expected to lead to the development of innovative therapies targeting pulmonary vascular remodeling.

Am J Physiol Lung Cell Mol Physiol. 2000 Feb;278(2):L335-43. (PMID: 10666118)
Nature. 2014 Jun 5;510(7503):92-101. (PMID: 24899309)
Hypertension. 2006 Apr;47(4):762-70. (PMID: 16505204)
Am J Pathol. 2005 Sep;167(3):835-48. (PMID: 16127161)
Int Arch Allergy Immunol. 2000 Mar;121(3):246-52. (PMID: 10729784)
N Engl J Med. 1992 Jul 9;327(2):70-5. (PMID: 1603138)
Br J Pharmacol. 1976 Feb;56(2):229-33. (PMID: 1252671)
Am J Physiol Lung Cell Mol Physiol. 2015 Oct 15;309(8):L776-88. (PMID: 26320154)
Nat Rev Immunol. 2016 Jan;16(1):51-67. (PMID: 26688348)
Science. 2019 Oct 18;366(6463):. (PMID: 31624181)
Eur Respir J. 2011 Jun;37(6):1400-10. (PMID: 21148228)
Front Physiol. 2022 Feb 17;13:819145. (PMID: 35250621)
Am J Respir Crit Care Med. 1998 Jan;157(1):219-29. (PMID: 9445303)
Nat Med. 2017 Nov;23(11):1287-1297. (PMID: 29035365)
J Clin Invest. 2012 Dec;122(12):4306-13. (PMID: 23202738)
J Heart Lung Transplant. 2015 Nov;34(11):1366-75. (PMID: 26210752)
Circulation. 2019 Oct 22;140(17):1409-1425. (PMID: 31462075)
Biomolecules. 2020 Oct 19;10(10):. (PMID: 33086624)
J Lipid Res. 2012 Jun;53(6):1093-105. (PMID: 22493087)
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1032-43. (PMID: 25180446)
Am J Physiol Heart Circ Physiol. 2014 Dec 1;307(11):H1547-58. (PMID: 25281570)
J Pharmacol Exp Ther. 2008 Dec;327(3):665-72. (PMID: 18784348)
J Immunol. 2007 Sep 1;179(5):2673-9. (PMID: 17709477)
PLoS One. 2015 Mar 18;10(3):e0120157. (PMID: 25785937)
Nat Immunol. 2007 Oct;8(10):1095-104. (PMID: 17767162)
Hypertension. 2021 Dec;78(6):1914-1926. (PMID: 34689593)
Am J Hypertens. 2016 May;29(5):598-604. (PMID: 26304959)
Am J Respir Crit Care Med. 2004 Mar 15;169(6):764-9. (PMID: 14701708)
Hypertension. 2021 Nov;78(5):1168-1184. (PMID: 34565184)
Eur J Pharmacol. 2016 May 5;778:103-15. (PMID: 25959384)
J Biol Chem. 2010 Oct 22;285(43):32720-32733. (PMID: 20732876)
Pharmacol Rev. 1994 Jun;46(2):205-29. (PMID: 7938166)
Eur J Immunol. 2003 Apr;33(4):899-906. (PMID: 12672055)
Immunol Lett. 2004 Mar 29;92(1-2):39-42. (PMID: 15081525)
N Engl J Med. 1996 Feb 1;334(5):296-301. (PMID: 8532025)
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1161-70. (PMID: 20622039)
Sci Transl Med. 2013 Aug 28;5(200):200ra117. (PMID: 23986401)
Pulm Circ. 2020 Mar 26;10(1):2045894019882635. (PMID: 32257113)
Am Rev Respir Dis. 1989 Sep;140(3):743-8. (PMID: 2782745)
Cell Physiol Biochem. 2018;51(1):487-500. (PMID: 30453304)
Chest. 2012 Mar;141(3):651-660. (PMID: 21940767)
J Exp Med. 2014 Jul 28;211(8):1673-87. (PMID: 25049337)
Front Immunol. 2022 Jun 27;13:923265. (PMID: 35833146)
Chest. 2012 Jan;141(1):210-221. (PMID: 22215829)
Sci Rep. 2022 Jun 16;12(1):10154. (PMID: 35710932)
Pharmacol Ther. 2018 Mar;183:177-204. (PMID: 29080699)
J Clin Invest. 2018 Aug 31;128(9):3727-3735. (PMID: 30168805)
Am J Respir Crit Care Med. 2011 Jul 1;184(1):116-23. (PMID: 21471108)
Nature. 1997 Dec 11;390(6660):618-22. (PMID: 9403692)
J Exp Med. 2018 Aug 6;215(8):2175-2195. (PMID: 29970474)
Eur Respir J. 2018 Jan 25;51(1):. (PMID: 29371380)
Nat Commun. 2022 May 31;13(1):3013. (PMID: 35641514)
Respiration. 2008;76(1):102-7. (PMID: 18349522)
Physiol Genomics. 2008 Apr 22;33(2):278-91. (PMID: 18303084)
Anesthesiology. 2012 Apr;116(4):882-95. (PMID: 22343473)
Am J Physiol Lung Cell Mol Physiol. 2017 May 1;312(5):L710-L721. (PMID: 28235950)
Thorax. 1976 Feb;31(1):94-100. (PMID: 130695)
Eur J Immunol. 2001 Nov;31(11):3298-307. (PMID: 11745347)
Circulation. 1982 Aug;66(2):334-8. (PMID: 7046988)
Naunyn Schmiedebergs Arch Pharmacol. 2012 Jul;385(7):657-70. (PMID: 22562473)
Front Immunol. 2014 Nov 14;5:569. (PMID: 25452755)
Nat Rev Cardiol. 2015 Nov;12(11):643-58. (PMID: 26259935)
J Appl Physiol Respir Environ Exerc Physiol. 1977 Feb;42(2):174-8. (PMID: 138666)
Eur Respir Rev. 2015 Dec;24(138):630-41. (PMID: 26621977)
Respir Res. 2011 May 02;12:60. (PMID: 21535881)
J Clin Invest. 2005 Oct;115(10):2811-21. (PMID: 16200212)
Cardiovasc Res. 2010 Jan 1;85(1):232-40. (PMID: 19679679)
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7. (PMID: 9113986)
J Immunol. 2010 Jan 1;184(1):433-41. (PMID: 20028661)
J Pharmacol Exp Ther. 2014 Jul;350(1):14-21. (PMID: 24763066)
Eur Respir J. 2015 Oct;46(4):1084-94. (PMID: 26113671)
Front Cardiovasc Med. 2021 Feb 01;8:624714. (PMID: 33598484)
Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545970)
Chest. 2016 Sep;150(3):680-93. (PMID: 27316557)
Pulm Circ. 2012 Apr-Jun;2(2):220-8. (PMID: 22837863)
J Cell Physiol. 2014 Feb;229(2):245-57. (PMID: 23982954)
J Appl Physiol Respir Environ Exerc Physiol. 1983 Mar;54(3):680-6. (PMID: 6841212)
Biomed Pharmacother. 2018 Dec;108:325-330. (PMID: 30227325)
J Pathol. 1970 Aug;101(4):Pi. (PMID: 5504730)
Eur Respir J. 2022 Jun 16;59(6):. (PMID: 34737219)
Circulation. 2013 Mar 12;127(10):1128-38. (PMID: 23403476)
Nat Rev Immunol. 2008 Jun;8(6):478-86. (PMID: 18483499)
J Clin Invest. 2018 Jul 2;128(7):2657-2669. (PMID: 29757195)
Am Rev Respir Dis. 1991 May;143(5 Pt 2):S100-2. (PMID: 2018248)
Am J Physiol Lung Cell Mol Physiol. 2018 May 1;314(5):L769-L781. (PMID: 29388467)
Pulm Circ. 2019 Jan-Mar;9(1):2045894018816977. (PMID: 30430898)
Biochim Biophys Acta. 2008 Sep;1781(9):563-70. (PMID: 18586114)
Arterioscler Thromb Vasc Biol. 2012 Jan;32(1):24-32. (PMID: 22015657)
Br J Pharmacol. 2022 Nov;179(22):5132-5147. (PMID: 35764296)
J Clin Invest. 2017 Nov 1;127(11):3987-4000. (PMID: 28990934)
J Cell Physiol. 2010 Jan;222(1):82-94. (PMID: 19746421)
Eur J Pharmacol. 2017 Sep 5;810:83-91. (PMID: 28576407)
Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L367-74. (PMID: 16199435)
Biochim Biophys Acta. 2012 Jan;1822(1):21-33. (PMID: 21185371)
Nat Rev Cardiol. 2019 Jul;16(7):389-406. (PMID: 30846875)
J Mol Cell Cardiol. 2020 Nov;148:50-62. (PMID: 32889002)
Circulation. 2008 Nov 11;118(20):2081-90. (PMID: 18955668)
Metabolites. 2022 Feb 25;12(3):. (PMID: 35323653)
J Exp Med. 1992 Jan 1;175(1):237-44. (PMID: 1370529)
Hypertension. 2011 Oct;58(4):679-88. (PMID: 21859965)
J Cardiovasc Pharmacol. 2011 Feb;57(2):140-7. (PMID: 20588188)
Front Med (Lausanne). 2021 Dec 22;8:806899. (PMID: 35004784)
Pulm Circ. 2015 Dec;5(4):640-8. (PMID: 26697171)
Front Immunol. 2016 Jan 06;6:620. (PMID: 26779180)
J Dermatol Sci. 2008 Jan;49(1):7-19. (PMID: 18024086)
BMJ. 2018 Mar 14;360:j5492. (PMID: 29540357)
Hypertension. 2015 Dec;66(6):1227-1239. (PMID: 26558820)
Circ Res. 2012 Apr 27;110(9):1179-91. (PMID: 22461388)
Prostaglandins Other Lipid Mediat. 2015 Jul;120:56-71. (PMID: 25917921)
Nat Med. 2007 Jun;13(6):719-24. (PMID: 17546038)
Cells. 2020 Oct 22;9(11):. (PMID: 33105588)
Science. 2000 Mar 17;287(5460):2013-7. (PMID: 10720327)

Keywords: lipid mediator; mast cell; n-3 epoxides; omega-3; pulmonary hypertension; remodeling

0 (Lysophospholipids)
0 (Fatty Acids, Unsaturated)

Date Created: 20230413 Date Completed: 20230414 Latest Revision: 20240314

20240315

PMC10094825

10.3390/ijms24076619

37047587